Table 1. Omicron RBD mutations with a demonstrated (X) or expected (x) reduction of binding or neutralization and based on our structural analyses.

	REGN10933	REGN10987	COV2-2196	COV2-2130	LY-CoV555	LY-CoV016	CT-P59	S309	ADI-58125	Total GISAID counts**	Omicron counts	VOC, VOI, VUM harboring mutation
G339D										196,756	192,125
S371L										182,692	179,486
S373P										185,025	181,374
S375F										184,990	181,461
K417N	X					X	X			116,510	70,903	Beta, K417T in Gamma
N440K										92,338	79,859
G446S		X		x						83,953	80,518
S477N	x		X			x				262,216	187,081
T478K			X							3,976,461	187,859	Delta
E484A	X			X	X		X			192,062	186,965	E484K in Beta, Gamma, Mu, Iota, Eta, Zeta, Theta; E484Q in Kappa
Q493R	X		X	x	X	x	X			191,484	188,353
G496S							X			187,583	184,575
Q498R							X			188,462	185,805
N501Y										1,434,752	186,285	Alpha, Beta, Theta, N501K in Mu
Y505H									X*	188,250	185,491
PDB ID	6XDG	6XDG	7L7D	7L7E	7KMG	7C01	7CM4	This study	n/a

* For ADI-58125, the impact on binding of C, N, and S substitutions is shown at position Y505 based on mutagenesis studies [J. Belk et al., WO2021207597 - Compounds Specific to Coronavirus S Protein and Uses Thereof. Adagio Therapeutics, Inc. (2021)].

**As of January 9, 2022; excluded entries with >5% Ns.